GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Urovant Sciences Ltd (NAS:UROV) » Definitions » ROC (Joel Greenblatt) %

Urovant Sciences (Urovant Sciences) ROC (Joel Greenblatt) % : -3,283.33% (As of Dec. 2020)


View and export this data going back to 2018. Start your Free Trial

What is Urovant Sciences ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Urovant Sciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2020 was -3,283.33%.

The historical rank and industry rank for Urovant Sciences's ROC (Joel Greenblatt) % or its related term are showing as below:

UROV's ROC (Joel Greenblatt) % is not ranked *
in the Biotechnology industry.
Industry Median: -333.95
* Ranked among companies with meaningful ROC (Joel Greenblatt) % only.

Urovant Sciences's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


Urovant Sciences ROC (Joel Greenblatt) % Historical Data

The historical data trend for Urovant Sciences's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Urovant Sciences ROC (Joel Greenblatt) % Chart

Urovant Sciences Annual Data
Trend Mar17 Mar18 Mar19 Mar20
ROC (Joel Greenblatt) %
- -7,262.16 -8,308.27 -4,397.63

Urovant Sciences Quarterly Data
Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3,544.68 -4,563.04 -2,433.44 -2,575.69 -3,283.33

Competitive Comparison of Urovant Sciences's ROC (Joel Greenblatt) %

For the Biotechnology subindustry, Urovant Sciences's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Urovant Sciences's ROC (Joel Greenblatt) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Urovant Sciences's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Urovant Sciences's ROC (Joel Greenblatt) % falls into.



Urovant Sciences ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Sep. 2020 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 9.445) - (18.763 + 0 + 9.584)
=-18.902

Working Capital(Q: Dec. 2020 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 14.759) - (33.367 + 0 + 6.549)
=-25.157

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Urovant Sciences for the quarter that ended in Dec. 2020 can be restated as:

ROC (Joel Greenblatt) %(Q: Dec. 2020 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2020  Q: Dec. 2020
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-181.24/( ( (5.315 + max(-18.902, 0)) + (5.725 + max(-25.157, 0)) )/ 2 )
=-181.24/( ( 5.315 + 5.725 )/ 2 )
=-181.24/5.52
=-3,283.33 %

Note: The EBIT data used here is four times the quarterly (Dec. 2020) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Urovant Sciences  (NAS:UROV) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Urovant Sciences ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Urovant Sciences's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Urovant Sciences (Urovant Sciences) Business Description

Traded in Other Exchanges
N/A
Address
11-12 St. James’s Square, Suite 1, 3rd Floor, London, GBR, SW1Y 4LB
Urovant Sciences Ltd is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing therapies for urologic conditions. The company's pipeline products include Overactive Bladder (OAB), OAB in Men with Benign Prostatic Hyperplasia (BPH), and IBS-Associated Pain.
Executives
Myrtle S Potter director 10 FINDERNE AVE, BRIDGEWATER NJ 08807
Sef Kurstjens director C/O UROVANT SCIENCES, INC. 5281 CALIFORNIA AVENUE, SUITE 100 IRVINE CA 92617
Pierre Legault director P.O. BOX 1028, C/O STONE MANAGEMENT LLC, BERWYNE PA 19312
James M. Hindman director 2525 DUPONT DRIVE, IRVINE CA 92612
Walt Johnston officer: SVP, Commercial, USI UROVANT SCIENCES LTD. 5281 CALIFORNIA AVE SUITE 100 IRVINE CA 92617
Haag-molkenteller Cornelia officer: CMO/Urovant Sciences, Inc. C/O UROVANT SCIENCES, INC. 5281 CALIFORNIA AVENUE, SUITE 100 IRVINE CA 92617
Bryan E. Smith officer: GC/Urovant Sciences, Inc. C/O UROVANT SCIENCES, INC., 5281 CALIFORNIA AVENUE, SUITE 100, IRVINE CA 92617
Christine Ocampo officer: PAO;CAO/Urovant Sciences, Inc C/O UROVANT SCIENCES, INC., 5281 CALIFORNIA AVENUE, SUITE 100, IRVINE CA 92617
Ajay Bansal officer: PFO;CFO/Urovant Sciences, Inc. C/O UROVANT SCIENCES, INC., 5281 CALIFORNIA AVENUE, SUITE 100, IRVINE CA 92617
Robinson James A. Jr. director, officer: PEO;CEO/Urovant Sciences, Inc. 852 WINTER STREET, WALTHAM MA 02451
Sumitomo Chemical Co., Ltd. other: See Footnote (1) 7-1, NIHONBASHI 2-CHOME, CHUO-KU, TOKYO M0 103-6020
Sumitovant Biopharma Ltd. 10 percent owner C/O ROIVANT SCIENCES, INC., 320 WEST 37TH STREET, 5TH FLOOR, NEW YORK NY 10018
Dainippon Sumitomo Pharma Co Ltd other: See Footnote (1) 6-8 DOSHOMACHI 2-CHOME, CHUO-KU, OSAKA M0 541-0045
Keith Katkin director, officer: PEO;CEO/Urovant Sciences, Inc. C/O UROVANT SCIENCES, INC., 5281 CALIFORNIA AVENUE, SUITE 100, IRVINE CA 92617
Shigeyuki Nishinaka director 5281 CALIFORNIA AVENUE, SUITE 100, IRVINE CA 92617

Urovant Sciences (Urovant Sciences) Headlines

From GuruFocus

Urovant Sciences to Report Second Fiscal Quarter 2020 Financial Results

By Business Wire Business Wire 10-27-2020

RM LAW Announces Investigation of Urovant Sciences Ltd.

By PRNewswire PRNewswire 11-19-2020